This company listing is no longer active
Resumen de acción INVV.Y
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de Indivior PLC
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | UK£21.85 |
| 52 Week High | UK£75.98 |
| 52 Week Low | UK£14.76 |
| Beta | -0.031 |
| 1 Month Change | -18.79% |
| 3 Month Change | 10.55% |
| 1 Year Change | 28.43% |
| 3 Year Change | 122.46% |
| 5 Year Change | -8.92% |
| Change since IPO | 90.79% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| INVV.Y | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -0.5% | 1.1% | 0.7% |
| 1Y | 28.4% | 9.5% | 23.9% |
Rentabilidad vs. Industria: INVV.Y exceeded the US Pharmaceuticals industry which returned 6.4% over the past year.
Rentabilidad vs. Mercado: INVV.Y exceeded the US Market which returned 14% over the past year.
Volatilidad de los precios
| INVV.Y volatility | |
|---|---|
| INVV.Y Average Weekly Movement | 20.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: INVV.Y's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: INVV.Y's weekly volatility has increased from 13% to 20% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 1,000 | Mark Crossley | www.indivior.com |
Resumen de fundamentos de Indivior PLC
| Estadísticas fundamentales de INVV.Y | |
|---|---|
| Capitalización bursátil | US$3.01b |
| Beneficios(TTM) | -US$50.00m |
| Ingresos (TTM) | US$947.00m |
3.2x
Ratio precio-ventas (PS)-60.2x
Ratio precio-beneficio (PE)¿Está INVV.Y sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de INVV.Y | |
|---|---|
| Ingresos | US$947.00m |
| Coste de los ingresos | US$161.00m |
| Beneficio bruto | US$786.00m |
| Otros gastos | US$836.00m |
| Beneficios | -US$50.00m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.36 |
| Margen bruto | 83.00% |
| Margen de beneficio neto | -5.28% |
| Ratio deuda/patrimonio | 331.9% |
¿Cómo se ha desempeñado INVV.Y a largo plazo?
Ver rendimiento histórico y comparativa